Syndicate Invests $26.7m in Microbiome Therapeutics Company BiomX


19 May 2017 --- A global syndicate which includes corporate venture funds Seventure Partners, Takeda Ventures and Johnson and Johnson Development Corporation has announced a $26.7 million (€24 million) investment in Israeli microbiome therapeutics company BiomX. 

BiomX focuses on developing novel therapeutics to alleviate human diseases stemming from dysbiosis of the microbiome. Its initial product candidates are based on bacteriophages (viruses which target and kill specific species or strains of bacteria). The company also uses unique technologies to identify microbiome targets for key diseases. 

The investment will be used for further developing BiomX’s drug candidate and obtain clinical proof of concept for the lead compound enabling the company to develop its world-leading IP and position itself as a major player in developing prescription-drug (Rx) therapeutics using scientific insights from its microbiome research.

“Since the beginning of the 20th Century, bacteriophage therapy has fascinated scientists by its ability to kill bacteria specifically and efficiently. But it lost out to antibiotics as a weapon against infectious diseases. BiomX is innovating by reviving this technology in the context of rebalancing the human microbiome to fight against chronic diseases,” says Eric de La Fortelle, Venture Partner at Seventure Partners.

Isabelle de Cremoux, CEO and Managing Partner of Seventure Partners, comments: “The microbiome field has is complex with multiple approaches having synergistic roles in healthcare. BiomX’s approach using bacteriophage seeks to harness natural mechanisms to restore a healthy microbiome balance to the gut. Israel is widely recognized for its expertise and innovation in life sciences, and our investment in a new region reflects how we are expanding our investment horizons internationally.”

Related Articles

Business News

LNC Therapeutics raises €6.5m to reinforce its R&D in the microbiota field

29 Sep 2017 --- LNC Therapeutics, a company specialized in the research and development of gut microbiota directed drugs for the treatment of obesity and associated cardiometabolic diseases, has raised a €6.5 million (US$7.67 million) Series C funding round. This new round, co-led by Seventure Partners, brings together a consortium of investors and a family office. Additionally, the company has appointed a new chief scientific officer, Dr. Sandrine Claus, to lead the gut microbiota project.

Nutrition & Health News

Gut Reaction – Microbiome Can Predict Body’s Response to Junk Foods

06 Jul 2017 --- Chemical signatures from gut bacteria which show up in urine can be used to predict how the body will respond to a “junk” diet. This is according to new research that has shown that certain compounds, produced by microbes in the guts of mice, could be used to show which animals are at greater risk of becoming obese or developing health conditions such as diabetes or cardiovascular disease (CVD).

Business News

Health for Life Capital Partakes in US$13.2m Financing of Japanese Microbiome Firm

05 Jul 2017 --- Seventure’s Health for Life Capital investment vehicle has participated in a US$13.1 million financing of Japanese biotech company Anaeropharma Science, Seventure Partners announced in a press release. Anaeropharma Science, based in Tokyo, Japan, is developing novel genetically enhanced bacteria to fight tumors. 

Business News

Personalized Nutrition Provider DayTwo Secures US$12m Series A Financing Round

04 Jul 2017 --- DayTwo, a company specialized in microbiome-health management, has completed a US$12 million Series A round of financing through Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Seventure Partners’ Health for Life Capital fund, Mayo Clinic, co-founder Marius Nacht and other private investors.

Nutrition & Health News

Microbiome Research is Pushing New Horizons: Seventure Partners

13 June 2017 --- Rapidly advancing understanding of the relationship between humans and their symbiotic microbes, and how their imbalance (dysbiosis) triggers or contributes to diseases will transform opportunities for novel nutritional, diagnostic and therapeutic products, says a new report by Seventure Partners, a French venture capital firm targeting life sciences companies.


More Articles